Affiliation:
1. Conju-probe, San Diego, California, USA
2. Department of Chemistry, Bharath University, Chennai, Tamil
Nadu, 600126, India
Abstract
Abstract:
This patent describes the series of compounds and their pharmaceutically acceptable
salts, such as compound K7 (as a representative potent compound). These protein
kinase C selective inhibitors are useful for treating diabetes mellitus and its complications,
cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease,
Alzheimer's disease, dermatological disease, virus diseases, inflammatory disorders, or
diseases in which the liver is a target organ.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Reference18 articles.
1. Sipka S.; Bíró T.; Czifra G.; Griger Z.; Gergely P.; Brugós B.; Tarr T.; The role of protein kinase C isoenzymes in the pathogenesis of human autoimmune diseases. Clin Immunol 2022,241,109071
2. Li H.; Nukui S.; Scales S.A.; Teng M.; Yin C.; Npyrimidin- 4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors. US Patent, US8877761B2, 2014
3. Botrous I.; Hong Y.; Li H.; Liu K.K.C.; Nukui S.; Teng M.; 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives as inhibitors of protein kinase c. European Patent, EP2195321B1, 2016
4. Cooke M.; Kazanietz M.G.; Overarching roles of diacylglycerol signaling in cancer development and antitumor immunity. Sci Signal 2022,15(729),eabo0264
5. He S.; Li Q.; Huang Q.; Cheng J.; Targeting protein kinase C for cancer therapy. Cancers 2022,14(5),1104